Syon Capital LLC Purchases Shares of 5,276 Insmed Incorporated (NASDAQ:INSM)

Syon Capital LLC acquired a new stake in Insmed Incorporated (NASDAQ:INSM - Free Report) in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 5,276 shares of the biopharmaceutical company's stock, valued at approximately $364,000.

A number of other institutional investors also recently bought and sold shares of the stock. National Bank of Canada FI boosted its position in Insmed by 9.7% in the fourth quarter. National Bank of Canada FI now owns 1,668 shares of the biopharmaceutical company's stock valued at $115,000 after buying an additional 147 shares during the last quarter. Abel Hall LLC boosted its holdings in shares of Insmed by 4.7% in the 4th quarter. Abel Hall LLC now owns 3,333 shares of the biopharmaceutical company's stock valued at $230,000 after acquiring an additional 151 shares during the last quarter. Steward Partners Investment Advisory LLC increased its stake in shares of Insmed by 65.2% in the fourth quarter. Steward Partners Investment Advisory LLC now owns 413 shares of the biopharmaceutical company's stock worth $29,000 after acquiring an additional 163 shares during the period. M&T Bank Corp increased its stake in shares of Insmed by 5.6% in the fourth quarter. M&T Bank Corp now owns 3,146 shares of the biopharmaceutical company's stock worth $217,000 after acquiring an additional 166 shares during the period. Finally, Nisa Investment Advisors LLC raised its holdings in shares of Insmed by 5.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 3,533 shares of the biopharmaceutical company's stock worth $244,000 after purchasing an additional 183 shares during the last quarter.

Insmed Stock Up 2.2 %

Shares of Insmed stock traded up $1.54 during trading hours on Tuesday, hitting $71.40. The company had a trading volume of 1,846,282 shares, compared to its average volume of 2,305,979. Insmed Incorporated has a twelve month low of $21.92 and a twelve month high of $84.91. The company has a market cap of $12.98 billion, a P/E ratio of -12.77 and a beta of 1.07. The company has a debt-to-equity ratio of 2.03, a current ratio of 6.37 and a quick ratio of 5.99. The company's 50-day moving average is $74.10 and its two-hundred day moving average is $73.54.

Insmed (NASDAQ:INSM - Get Free Report) last posted its quarterly earnings data on Thursday, February 20th. The biopharmaceutical company reported ($1.32) earnings per share for the quarter, missing the consensus estimate of ($1.17) by ($0.15). The firm had revenue of $104.44 million during the quarter, compared to analyst estimates of $102.31 million. Insmed had a negative net margin of 251.24% and a negative return on equity of 4,773.73%. Analysts anticipate that Insmed Incorporated will post -4.56 earnings per share for the current fiscal year.

Analyst Ratings Changes

INSM has been the topic of several analyst reports. Morgan Stanley increased their price target on Insmed from $85.00 to $90.00 and gave the stock an "overweight" rating in a research report on Thursday, February 6th. Bank of America lifted their price objective on shares of Insmed from $92.00 to $96.00 and gave the company a "buy" rating in a report on Thursday, March 20th. Guggenheim reaffirmed a "buy" rating and set a $101.00 target price on shares of Insmed in a research note on Tuesday, February 25th. Truist Financial upped their price target on shares of Insmed from $105.00 to $108.00 and gave the stock a "buy" rating in a research report on Friday, February 21st. Finally, Stifel Nicolaus decreased their price objective on Insmed from $97.00 to $96.00 and set a "buy" rating on the stock in a report on Friday, February 21st. One investment analyst has rated the stock with a sell rating and sixteen have issued a buy rating to the stock. According to data from MarketBeat.com, Insmed presently has a consensus rating of "Moderate Buy" and a consensus price target of $94.00.

Insiders Place Their Bets

In other Insmed news, insider Orlov S. Nicole Schaeffer sold 91,140 shares of Insmed stock in a transaction that occurred on Thursday, January 30th. The stock was sold at an average price of $80.00, for a total value of $7,291,200.00. Following the sale, the insider now owns 97,083 shares of the company's stock, valued at approximately $7,766,640. The trade was a 48.42 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Martina M.D. Flammer sold 33,055 shares of the stock in a transaction on Thursday, February 6th. The stock was sold at an average price of $80.90, for a total value of $2,674,149.50. Following the completion of the transaction, the insider now owns 138,053 shares of the company's stock, valued at $11,168,487.70. The trade was a 19.32 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 471,797 shares of company stock valued at $37,621,239. 3.00% of the stock is owned by company insiders.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.